Linsitinib (OSI-906)

For research use only.

Catalog No.S1091

91 publications

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEK4NFYh|ryP MVLTRW5ITVJ?
KS-1 NU\nVIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7hTWM2OD1yLkCzPFM2KM7:TR?= NVrJWnNGW0GQR1XS
TE-11 NXT2OIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoTWM2OD1yLkC3PFIzKM7:TR?= NEfUWWdUSU6JRWK=
EW-1 M3nDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLZTWM2OD1yLkC4OVg2KM7:TR?= M3vEZnNCVkeHUh?=
HMV-II MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHJPXJKSzVyPUCuNFg5PDZizszN MXTTRW5ITVJ?
COLO-205 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPMTWM2OD1yLkGwOFU1KM7:TR?= MVvTRW5ITVJ?
ES1 NEDucldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyye5VKSzVyPUCuNVA3QTZizszN NFrWV4RUSU6JRWK=
GDM-1 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e5TGlEPTB;MD6xN|Y4OiEQvF2= MYHTRW5ITVJ?
ML-2 NEHUOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1niU2lEPTB;MD6xOVg6PiEQvF2= Mn;LV2FPT0WU
Saos-2 NGnOd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjN[Ip5UUN3ME2wMlE3PTJ4IN88US=> MVPTRW5ITVJ?
NCI-H1355 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUixN|Uh|ryP NETXVHNUSU6JRWK=
G-401 M1HZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvXXYFHUUN3ME2wMlE5OjNizszN M{DiO3NCVkeHUh?=
EW-16 NF2wVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D4TmlEPTB;MD6xPFc4PyEQvF2= MV3TRW5ITVJ?
EW-7 NEDP[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pq[mlEPTB;MD6xPFg5OSEQvF2= M4nMdHNCVkeHUh?=
NCI-H727 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUm3PVQh|ryP NYWwUJVVW0GQR1XS
LCLC-97TM1 NE\sbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\3e5FKSzVyPUCuNlA6PTVizszN MlHIV2FPT0WU
NCI-H650 NUXaPW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjzfFVKSzVyPUCuNlE{QDRizszN NGPYWndUSU6JRWK=
NCI-H2122 NHjCOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpZ2lEPTB;MD6yN|I6QSEQvF2= M{CwcXNCVkeHUh?=
SK-N-DZ MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSzb4F6UUN3ME2wMlI{Pjl6IN88US=> NGnPc3ZUSU6JRWK=
HT-29 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq4XYxnUUN3ME2wMlI1OjR6IN88US=> MX;TRW5ITVJ?
LB771-HNC NF3JXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHEWmNkUUN3ME2wMlI2QTF3IN88US=> MVnTRW5ITVJ?
HT-144 M3v3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMk[xPVEh|ryP NXLnSoU3W0GQR1XS
LAN-6 NYiwcnV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULHRnlOUUN3ME2wMlI3OzR6IN88US=> MoTjV2FPT0WU
EW-18 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzD[olDUUN3ME2wMlI4ODBzIN88US=> NH\GV4pUSU6JRWK=
LS-1034 NGG5Wo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMkexN|Ih|ryP M37aNHNCVkeHUh?=
EW-11 M2DQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlroTWM2OD1yLkK4OFMzKM7:TR?= NH3NOXhUSU6JRWK=
SNU-C1 NUL3[|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LuT2lEPTB;MD6yPVMyOyEQvF2= M2rNO3NCVkeHUh?=
RS4-11 NIX0XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwM{O3OVgh|ryP M4DCRnNCVkeHUh?=
ES4 M2\KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNEGwN|gh|ryP NWnScGFKW0GQR1XS
COLO-320-HSR NEftPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEGzOlgh|ryP NYnIToplW0GQR1XS
NB10 NGXwTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XodmlEPTB;MD60OVQ{PyEQvF2= MV7TRW5ITVJ?
BFTC-905 NUWyT4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNE[3OVgh|ryP MkfGV2FPT0WU
A375 NWm5OlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHaenZKSzVyPUCuOFc3OTdizszN MVfTRW5ITVJ?
SJRH30 NG[1PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HGUGlEPTB;MD61NFgzOiEQvF2= NXrpbIU2W0GQR1XS
NOS-1 NYDSdppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLFTFZKSzVyPUCuOVIzPjdizszN M{TxdHNCVkeHUh?=
SIG-M5 NXW1NJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M130fmlEPTB;MD61N|U2PyEQvF2= NUDZZmtLW0GQR1XS
DOK MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;y[HpPUUN3ME2wMlU2PiEQvF2= NHLQ[HRUSU6JRWK=
NB69 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwNUiyOVch|ryP MkTpV2FPT0WU
SK-NEP-1 NF[zO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Tx[GlEPTB;MD62NFI{PiEQvF2= M2PQOHNCVkeHUh?=
SK-MM-2 NFTlNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPYTWM2OD1yLk[1OFkyKM7:TR?= MVLTRW5ITVJ?
NCI-H358 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[0TWM2OD1yLk[3NFgzKM7:TR?= NVTDTnVPW0GQR1XS
RH-1 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvIdVN2UUN3ME2wMlc1QDV7IN88US=> MU\TRW5ITVJ?
NH-12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4W2lEPTB;MD63OlA1PiEQvF2= NUfYNINsW0GQR1XS
TE-12 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L5c2lEPTB;MD63OlQ5PiEQvF2= MkTJV2FPT0WU
COLO-668 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn1TWM2OD1yLki0OlY3KM7:TR?= NFzLNIFUSU6JRWK=
PANC-08-13 NGL3PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm4S4RQUUN3ME2wMlg3Ozd5IN88US=> NXHvPJlWW0GQR1XS
HCC2998 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOEiyOlMh|ryP MnHMV2FPT0WU
ABC-1 NUP0PXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6SFUxUUN3ME2wMlkxOzV{IN88US=> MUXTRW5ITVJ?
ES6 NH3iW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzxPXVKSzVyPUCuPVExPjZizszN MoTWV2FPT0WU
SNU-387 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwOUmzPVMh|ryP NHPIbopUSU6JRWK=
CMK NHjST2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LqTGlEPTB;MD65PVkzQSEQvF2= NVyxcpF2W0GQR1XS
SJSA-1 NFqzXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjaUZdTUUN3ME2xMlA{PjV|IN88US=> NF7PfoNUSU6JRWK=
SIMA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfDO3RKSzVyPUGuNFY5OjVizszN M{HmdnNCVkeHUh?=
ES3 NGHDdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HkUGlEPTB;MT6xNlI6PyEQvF2= NGTlNpVUSU6JRWK=
IGROV-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD1zLkG1OFQ1KM7:TR?= MlTsV2FPT0WU
MEL-JUSO MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jJVGlEPTB;MT6xOVc2QSEQvF2= NIXKcXZUSU6JRWK=
T84 M2\6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTZe2VKSzVyPUGuNlA6OTRizszN MXfTRW5ITVJ?
CAL-85-1 M{\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTvTWM2OD1zLkKzNVM5KM7:TR?= NXfMTIRsW0GQR1XS
RD NG\SU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqyXVZTUUN3ME2xMlI3PDV3IN88US=> MojuV2FPT0WU
TE-8 NVy2dodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SxS2lEPTB;MT6zNVQ3OiEQvF2= MWfTRW5ITVJ?
L-363 NVfLN5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHNTWM2OD1zLkO0NlA5KM7:TR?= NEXqTmlUSU6JRWK=
EKVX MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK4PGxKSzVyPUGuN|Q2PjhizszN M3:4T3NCVkeHUh?=
SK-MEL-3 M1rSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD1zLkS4OVU3KM7:TR?= NXrMWo14W0GQR1XS
TGBC24TKB MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsTWM2OD1zLkWwNVk{KM7:TR?= MlixV2FPT0WU
NCI-H1770 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDYPZVKSzVyPUGuOVEyOTNizszN MnnyV2FPT0WU
HuH-7 NX\lZodIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrUc|lKSzVyPUGuOlAxQThizszN NHSxNohUSU6JRWK=
HL-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHlXmpKSzVyPUGuOlY6OjhizszN M{\nOXNCVkeHUh?=
TE-1 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHvTWM2OD1zLkewPVQ2KM7:TR?= NGLuemhUSU6JRWK=
LC-2-ad M3flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwN{O4PFch|ryP MkG5V2FPT0WU
LB647-SCLC M1KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBWWtKSzVyPUGuO|Y2QDNizszN NEPZSopUSU6JRWK=
NCI-H2171 NFHJOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXDUoRFUUN3ME2xMlc4PzF4IN88US=> NX\0cYxoW0GQR1XS
SK-PN-DW MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fIW2lEPTB;MT65NVI6QCEQvF2= NHLMZm1USU6JRWK=
MC-IXC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHwTWM2OD1zLkm4PVgh|ryP NIrFdmlUSU6JRWK=
LS-513 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwMEWzNFUh|ryP NEHHPHdUSU6JRWK=
EW-3 M2Xnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnSVHFKSzVyPUKuNFk5PDRizszN MUjTRW5ITVJ?
OPM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmwTWM2OD1{LkGwNkDPxE1? MlrwV2FPT0WU
LP-1 M2DsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjvd4ZKSzVyPUKuNlU5ODdizszN MkHKV2FPT0WU
LU-134-A M2DQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fHbmlEPTB;Mj6yO|ch|ryP MVvTRW5ITVJ?
CP66-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLYOYdKSzVyPUKuNlkxOTRizszN M2LpeHNCVkeHUh?=
HCC1143 NHjIU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHOTWM2OD1{LkS1N|Y5KM7:TR?= NGDoWWhUSU6JRWK=
LOXIMVI M2jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLzXJE3UUN3ME2yMlYxOjFizszN MUPTRW5ITVJ?
TE-10 NXT6U2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTkR2lKSzVyPUKuO|A5OzhizszN MVPTRW5ITVJ?
NCI-H1882 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:0S2FsUUN3ME2yMlc2OjJ5IN88US=> M3vMTHNCVkeHUh?=
CHP-126 NEjhdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\wRlVLUUN3ME2yMlc3OzF5IN88US=> MkTIV2FPT0WU
NCI-H1623 NVHDZoRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zR[WlEPTB;Mj65NlAzPCEQvF2= M3jES3NCVkeHUh?=
GB-1 NX35PIhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrUVnNxUUN3ME2yMlk{PDB2IN88US=> M1rScHNCVkeHUh?=
RCC10RGB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;0XoJKSzVyPUKuPVUzQDFizszN M2PRUXNCVkeHUh?=
NCI-H2141 M{HtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXRTWM2OD1{Lkm2PFk3KM7:TR?= MXnTRW5ITVJ?
GI-ME-N MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDIR3RKSzVyPUOuNFA2PjVizszN NIjUSnhUSU6JRWK=
NCI-H526 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwMESwPFUh|ryP M2[2XHNCVkeHUh?=
NCI-H747 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\LelNFUUN3ME2zMlA1QTl{IN88US=> NIHye2VUSU6JRWK=
SNU-423 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwMkCzNVMh|ryP NEHacZVUSU6JRWK=
A427 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\OWWdKSzVyPUOuNlU3QTlizszN NXiycHVQW0GQR1XS
CAL-12T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOzSG1KSzVyPUOuOFA4OTNizszN NGr6VZlUSU6JRWK=
LU-99A MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yd25xUUN3ME2zMlQ4OTB3IN88US=> MVrTRW5ITVJ?
MS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\5PIxKSzVyPUOuOVM1OjlizszN MYDTRW5ITVJ?
SK-LU-1 NFjWZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DUT2lEPTB;Mz63OlI6PSEQvF2= NET4PFhUSU6JRWK=
SW837 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTmVFFKSzVyPUOuO|Y{OzNizszN NXnsNWxRW0GQR1XS
ES8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH6SZc3UUN3ME2zMlg{QDd5IN88US=> MnzXV2FPT0WU
MZ2-MEL M1jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwUHhKSzVyPUOuPVIxQDZizszN MlXEV2FPT0WU
TGW MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLHUXpvUUN3ME20MlAyOzFzIN88US=> M1[wcXNCVkeHUh?=
GP5d NFP3ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P6fmlEPTB;ND6wOVM3OiEQvF2= NV7HSph6W0GQR1XS
BB49-HNC Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqzOZdKSzVyPUSuNVUzOTNizszN MXfTRW5ITVJ?
NB13 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\OTWM2OD12LkK2PFg4KM7:TR?= MkTjV2FPT0WU
NTERA-S-cl-D1 NUjjdnFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHxOlhKSzVyPUSuNlg3OTVizszN M4PBZXNCVkeHUh?=
NCI-H1648 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGUWxKSzVyPUSuNlk5OTlizszN MXTTRW5ITVJ?
LCLC-103H NYDsVFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRwM{KxPVUh|ryP MmnyV2FPT0WU
LS-411N NFTlXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRwNES4PFUh|ryP NHX3No1USU6JRWK=
NCI-H1092 NV3wN4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzhTWM2OD12LkS1Olg4KM7:TR?= MYPTRW5ITVJ?
PANC-10-05 M1nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Ve4ZKSzVyPUSuOlk5PCEQvF2= MYjTRW5ITVJ?
DK-MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\0TWM2OD12LkiwPVM{KM7:TR?= NWfWeIltW0GQR1XS
OVCAR-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRwOEGyNlYh|ryP MojiV2FPT0WU
CAL-39 M4O3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13mZ2lEPTB;ND64O|Y4KM7:TR?= MVHTRW5ITVJ?
TE-441-T M1[2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7SZXNKSzVyPUSuPVA2OzdizszN NULoOpk1W0GQR1XS
MOLT-16 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HhSGlEPTB;ND65OVI2OyEQvF2= NVnqWYlKW0GQR1XS
MCF7 NELEUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD13LkG0OVE4KM7:TR?= Mnv6V2FPT0WU
CAPAN-1 M4TyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrvSGRvUUN3ME21MlI2PzB5IN88US=> MV;TRW5ITVJ?
PSN1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWU2lEPTB;NT6yO|I{PSEQvF2= NGTTXpFUSU6JRWK=
NCI-H292 NH6xXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfkVlJHUUN3ME21MlMxODR2IN88US=> NWm4O3g5W0GQR1XS
CPC-N NWXabVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyzPZFKSzVyPUWuN|k1OTlizszN M4XJU3NCVkeHUh?=
DoTc2-4510 M1vFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXLXGVKSzVyPUWuOFU{PzFizszN NX3uSo9uW0GQR1XS
LB1047-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjxdmtJUUN3ME21MlU2QTN|IN88US=> MnTvV2FPT0WU
MHH-ES-1 NHP2VI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPm[WFQUUN3ME21MlU6QTB5IN88US=> M4\EO3NCVkeHUh?=
NMC-G1 NX;IWGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M324W2lEPTB;NT63NFIzPyEQvF2= MWnTRW5ITVJ?
SW1710 M4joXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M324eWlEPTB;NT63OFc2OSEQvF2= M1j3fHNCVkeHUh?=
YAPC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;FXZRKSzVyPUWuO|YzODFizszN NFLsbVlUSU6JRWK=
22RV1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK1TWM2OD13LkiwNFE6KM7:TR?= Mlm3V2FPT0WU
COLO-679 M{L5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPpN5hKSzVyPUWuPFg6PDhizszN MmjzV2FPT0WU
TCCSUP NHnYbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwOUOyOVkh|ryP NYD0OmVpW0GQR1XS
C2BBe1 NIDxXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf3NphKSzVyPUWuPVM6PyEQvF2= M2f2bXNCVkeHUh?=
TE-15 M33PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn2TWM2OD14LkC2OlA2KM7:TR?= MYjTRW5ITVJ?
SCLC-21H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37ZcGlEPTB;Nj6xNFg1OyEQvF2= NGfqRZlUSU6JRWK=
EoL-1-cell MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXuTWM2OD14LkG2OVY{KM7:TR?= MUDTRW5ITVJ?
NKM-1 NX3CTnRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwMU[3NUDPxE1? M1fkenNCVkeHUh?=
NCI-H1304 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTZwMke0Nlgh|ryP MmHQV2FPT0WU
NB6 M4K3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWwPFNKSzVyPU[uNlk3OjJizszN NGrqZ4xUSU6JRWK=
NALM-6 M2\pUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwM{OyN{DPxE1? NWTHTYVrW0GQR1XS
NCI-H522 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwM{OzNFYh|ryP NEm3e2RUSU6JRWK=
MV-4-11 M2PH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfiW49KSzVyPU[uN|cxPzlizszN NVnCOlF4W0GQR1XS
LB2241-RCC NVPIZVhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwM{i2Olch|ryP MmTEV2FPT0WU
NCI-H1417 NWj2RpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\0UldKSzVyPU[uOFA5PDdizszN NVXFUWNUW0GQR1XS
HT-1197 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrjWFRkUUN3ME22MlU4OTJ{IN88US=> MVnTRW5ITVJ?
P30-OHK M{Lycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXTZ2VVUUN3ME22MlYzPzdizszN NVTuOI1DW0GQR1XS
ALL-PO M4HTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL1VJlQUUN3ME22MlcyQTF4IN88US=> MV\TRW5ITVJ?
OVCAR-4 M2PUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD5V3NKSzVyPU[uO|U1ODVizszN NIDiOolUSU6JRWK=
HCC2157 M33aNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXpTWM2OD14Lke3OFc2KM7:TR?= MVvTRW5ITVJ?
NCI-H838 NVjY[5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLKTWM2OD14Lkm2OFkh|ryP MW\TRW5ITVJ?
NCI-H1299 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK5TWM2OD14Lkm3NFkh|ryP MoHoV2FPT0WU
SW954 NG\LbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jcYlSUUN3ME23MlIxODZ6IN88US=> NH7aPWVUSU6JRWK=
NCI-H441 M3v1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTdwM{SwOlUh|ryP M3q1WXNCVkeHUh?=
SK-MEL-2 NF\oO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnvOllRUUN3ME23MlQ5Ozd|IN88US=> MVzTRW5ITVJ?
KARPAS-45 NV[3cYxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrBTWM2OD15Lk[1PVI6KM7:TR?= MmrqV2FPT0WU
CAL-54 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wTWM2OD15LkiyPVc4KM7:TR?= MVHTRW5ITVJ?
KYSE-180 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmzeJdHUUN3ME23Mlg5QTRzIN88US=> M2\GcHNCVkeHUh?=
NCI-H187 NUfSU216T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwOUW5OFch|ryP NWq2e|g2W0GQR1XS
RT-112 NFntUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4faV2lEPTB;OD6wPVY4PyEQvF2= MUDTRW5ITVJ?
NCI-H1437 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnJU|dmUUN3ME24MlA6Pzl3IN88US=> MV3TRW5ITVJ?
SNU-449 NIe2NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LRc2lEPTB;OD6yPFI4OiEQvF2= NHzYbmhUSU6JRWK=
HCC1187 M{\jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPGTWM2OD16LkK5N|kyKM7:TR?= MVPTRW5ITVJ?
NCI-H2030 M4XnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnDXJNRUUN3ME24MlM4PzF2IN88US=> MUnTRW5ITVJ?
HuO-3N1 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRThwM{e4OFQh|ryP NUTwNVlMW0GQR1XS
COLO-792 NXPrTJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrwOZpKSzVyPUiuOFE2OjdizszN MmfiV2FPT0WU
MIA-PaCa-2 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqze2RvUUN3ME24Mlg2PTB6IN88US=> MmfxV2FPT0WU
SK-N-FI MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T5OWlEPTB;OT6wOFI2KM7:TR?= NFrtNXJUSU6JRWK=
MMAC-SF NULjfnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVznZZJLUUN3ME25MlA6PzVzIN88US=> MV3TRW5ITVJ?
NCI-H28 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTlwMUC0Olkh|ryP MljCV2FPT0WU
ETK-1 NYXkdYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTlwMkm5O|Qh|ryP NF7ybHJUSU6JRWK=
NCI-H1993 NYjvZ4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwNESyOlEh|ryP NGDGW3dUSU6JRWK=
no-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37nR2lEPTB;OT60O|EzKM7:TR?= MlS5V2FPT0WU
ChaGo-K-1 NGLzeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTlVGlKSzVyPUmuOVE2QDNizszN MmXOV2FPT0WU
NCCIT NIjzfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\3TlJGUUN3ME25MlU{OTZ7IN88US=> NYPofGJZW0GQR1XS
SAS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPs[oJKSzVyPUGwMlI1QCEQvF2= Mnz0V2FPT0WU
A673 NHXNU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jCT2lEPTB;MUCuN|cxPCEQvF2= M1PW[3NCVkeHUh?=
NCI-H1522 M{LudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD1zMD6zO|A4KM7:TR?= NHrmWnhUSU6JRWK=
NCI-H810 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFyLkO5NFch|ryP M321cXNCVkeHUh?=
IST-MES1 NVvKOWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKd5VPUUN3ME2xNE41PTZ2IN88US=> MX\TRW5ITVJ?
GR-ST NXm4WG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD6TWM2OD1zMD61NFI1KM7:TR?= MYXTRW5ITVJ?
SUP-T1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPWZoxKSzVyPUGwMlc{OTdizszN MWnTRW5ITVJ?
NB5 NF3JUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljPTWM2OD1zMD65NFIzKM7:TR?= MkTZV2FPT0WU
MZ1-PC M4fFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M330VGlEPTB;MUCuPVU4OSEQvF2= NFnlNm1USU6JRWK=
SK-CO-1 M3fZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\w[GJKSzVyPUGwMlk6OzFizszN MV\TRW5ITVJ?
Capan-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\sTVNKSzVyPUGxMlMyQThizszN Mn;HV2FPT0WU
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\XS3NxUUN3ME2xNU43PzV5IN88US=> NXn3endsW0GQR1XS
REH M4T3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMeWlEPTB;MUGuO|Q2OSEQvF2= NF7aTGdUSU6JRWK=
GI-1 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfwVVRKSzVyPUGxMlg3OTVizszN NYHhW3BrW0GQR1XS
BB65-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1zMj6wPVE3KM7:TR?= M3rGcXNCVkeHUh?=
NCI-H1651 NF72fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF{LkK0O|gh|ryP MnLaV2FPT0WU
NCI-H1618 NGPkTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICyVmlKSzVyPUGyMlM6PzZizszN MYjTRW5ITVJ?
NCI-H2081 NF\PVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jLeWlEPTB;MUKuOlE1OSEQvF2= M{G4XXNCVkeHUh?=
GCIY MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF{LkeyNVMh|ryP MmmwV2FPT0WU
NY MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[zZZBpUUN3ME2xN{4xPjR|IN88US=> NHvv[5lUSU6JRWK=
PANC-03-27 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4TWM2OD1zMz6wPFA4KM7:TR?= MXjTRW5ITVJ?
BHY Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYniS2NMUUN3ME2xN{4zOTJzIN88US=> MkHlV2FPT0WU
SK-OV-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF|LkO3OlMh|ryP M4H0TXNCVkeHUh?=
5637 NUT0V4IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK1bnJRUUN3ME2xN{44PzV7IN88US=> MYDTRW5ITVJ?
LC-1F NHnpfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTLTWM2OD1zND6wN|U3KM7:TR?= NVf4SnE3W0GQR1XS
SNB75 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF2LkCzPFMh|ryP MUnTRW5ITVJ?
CHP-212 NVfsSGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfjb2tXUUN3ME2xOE4xPDZ2IN88US=> M3PMTXNCVkeHUh?=
HT-1376 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXrcHk2UUN3ME2xOE4yOTJ4IN88US=> NGK0UZhUSU6JRWK=
MONO-MAC-6 NXq0NJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF2LkG1NFIh|ryP MmD5V2FPT0WU
CA46 NFvVU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn6[Y5KSzVyPUG0MlE5OjdizszN M4LwRXNCVkeHUh?=
SCC-15 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\SRopnUUN3ME2xOE42PTh|IN88US=> NH\pXpBUSU6JRWK=
ATN-1 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF2Lk[2Nlch|ryP MnezV2FPT0WU
NCI-H2405 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziTWM2OD1zND64NVU4KM7:TR?= NX\CNVUyW0GQR1XS
NCI-H716 NVH1SFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rtSGlEPTB;MUSuPFQ6OyEQvF2= Mk\RV2FPT0WU
SW620 NWfheWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF2LkmwNVQh|ryP NFHzWWFUSU6JRWK=
NCI-H226 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37CSWlEPTB;MUSuPVA5PSEQvF2= MmXNV2FPT0WU
SW962 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7tTWM2OD1zND65OFMzKM7:TR?= MX7TRW5ITVJ?
KYSE-150 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD1zND65OVUh|ryP MlT4V2FPT0WU
OCUB-M NHHF[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTvTWM2OD1zND65PFg{KM7:TR?= NH;t[IJUSU6JRWK=
ES7 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\iTVBEUUN3ME2xOU4xQTh2IN88US=> NVXxN2x7W0GQR1XS
SW1463 NVv0TG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfMTWM2OD1zNT60NlI{KM7:TR?= NYPuRZlvW0GQR1XS
CAKI-1 M2DEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLUc|FYUUN3ME2xOU42OzR4IN88US=> NH;GOI9USU6JRWK=
MKN28 NFnxcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jMdGlEPTB;MUWuOVQ4QSEQvF2= MWDTRW5ITVJ?
SW13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonhTWM2OD1zNT62NVgh|ryP MWDTRW5ITVJ?
A3-KAW M2XNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojoTWM2OD1zNT65Olk4KM7:TR?= MUXTRW5ITVJ?
LU-65 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewWWlEPTB;MUWuPVc3QCEQvF2= M1\BTXNCVkeHUh?=
Calu-1 M4e2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfa[YlKSzVyPUG2MlA{PjhizszN MWTTRW5ITVJ?
ST486 NHjpN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPsNIVKSzVyPUG2MlA1OzFizszN MWfTRW5ITVJ?
BB30-HNC M{D0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF32TnpKSzVyPUG2MlEzPDZizszN MX7TRW5ITVJ?
EGI-1 M2DHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfISXRKSzVyPUG2MlQ1PiEQvF2= M2ftPXNCVkeHUh?=
SH-4 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjCfVNFUUN3ME2xOk41PzNzIN88US=> MnG2V2FPT0WU
MN-60 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPFTWM2OD1zNz6yNlk4KM7:TR?= MVjTRW5ITVJ?
MPP-89 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXNTWM2OD1zNz6yOFU6KM7:TR?= M4HTXHNCVkeHUh?=
A2780 NH;MRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1zNz60NVM6KM7:TR?= NGHWcFVUSU6JRWK=
Daoy MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqd29zUUN3ME2xO{41Pjl3IN88US=> NIXLdm9USU6JRWK=
NCI-H2126 NVXHZVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L4TGlEPTB;MUeuOFc4OSEQvF2= NE\T[YZUSU6JRWK=
NCI-H1563 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS2TW5KSzVyPUG3MlQ6OTdizszN M1zRb3NCVkeHUh?=
8-MG-BA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjqXGhKSzVyPUG3MlY3PDhizszN NVrPb|l7W0GQR1XS
786-0 NHfk[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF5LkizOVMh|ryP M4PndnNCVkeHUh?=
AM-38 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwNm5KSzVyPUG3Mlk{ODZizszN NV:0W2VCW0GQR1XS
COLO-824 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPN[mVHUUN3ME2xPE41PDN4IN88US=> MmrhV2FPT0WU
SK-MEL-30 NXPYbItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF6LkWwPFIh|ryP MVHTRW5ITVJ?
CESS NH7EN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPEUI9KSzVyPUG4Mlc3ODlizszN MXHTRW5ITVJ?
BL-70 NWHReGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHVWo5KSzVyPUG4MlgyPTZizszN Ml\QV2FPT0WU
NCI-H2170 M3L2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPVTWM2OD1zOD65NVc6KM7:TR?= MmTEV2FPT0WU
HT-3 M{HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXQTW9oUUN3ME2xPE46QDNizszN MmLmV2FPT0WU
BOKU NGnsO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqdpNxUUN3ME2xPU4xOzhzIN88US=> M1PrSnNCVkeHUh?=
HPAF-II NXXZN3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJPXFZUUN3ME2xPU4{ODF3IN88US=> NF;6RWFUSU6JRWK=
KGN NVu4XIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\V[2FKSzVyPUG5MlQ4PjVizszN NVPZeZpWW0GQR1XS
MC-CAR NWX6[ZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPaVng5UUN3ME2xPU43OzF|IN88US=> MnTJV2FPT0WU
BHT-101 NV\tcmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmwTWM2OD1zOT63O|ch|ryP Mn3PV2FPT0WU
SW1783 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[zZ2JCUUN3ME2xPU44QDB4IN88US=> NUHDTVlXW0GQR1XS
KP-N-YN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL5NWtjUUN3ME2yNE4xOjZ{IN88US=> Mn7ZV2FPT0WU
LU-165 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OwTmlEPTB;MkCuOVU4OSEQvF2= NV\JNHJXW0GQR1XS
GOTO NGi0U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TC[mlEPTB;MkCuOlQ2OSEQvF2= M4fzeHNCVkeHUh?=
EFM-19 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PDXmlEPTB;MkGuNFcyPiEQvF2= NInLfpRUSU6JRWK=
CTV-1 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHDfHlKSzVyPUKxMlExPTRizszN MV3TRW5ITVJ?
HEL NU\Gb5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJzLkSyNVYh|ryP NGmySYxUSU6JRWK=
SNU-C2B MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fRdmlEPTB;MkGuOFI3KM7:TR?= MWfTRW5ITVJ?
ECC4 NGi5OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJzLkewO{DPxE1? MXTTRW5ITVJ?
NEC8 M2jrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL0dGZKSzVyPUKxMlg{PjhizszN MXrTRW5ITVJ?
KMOE-2 M2\vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P2eGlEPTB;MkGuPFkzOSEQvF2= MX\TRW5ITVJ?
NCI-H524 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTr[3pKSzVyPUKyMlA5ODhizszN MVTTRW5ITVJ?
WSU-NHL M1Pvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[ycYFQUUN3ME2yNk4yPTd5IN88US=> M2iwTHNCVkeHUh?=
SF126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i1cWlEPTB;MkKuNlQ3QSEQvF2= NVnLVFROW0GQR1XS
HOP-92 NIjVfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfXPGVCUUN3ME2yNk4{OTZ5IN88US=> MYjTRW5ITVJ?
CTB-1 NEjaXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ{LkS2O|ch|ryP M1XYR3NCVkeHUh?=
KYSE-270 NYXZb4pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPGWYFKSzVyPUKyMlk{PTdizszN NEfqbGVUSU6JRWK=
SK-MEL-24 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ|LkG4O{DPxE1? MUHTRW5ITVJ?
Calu-3 NETWcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ|LkKxNlgh|ryP NUfNVGJpW0GQR1XS
GAMG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWzUnJoUUN3ME2yN{4zOzZ5IN88US=> NWLKTItoW0GQR1XS
SW1573 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ|Lke0NVUh|ryP Ml;MV2FPT0WU
MHH-NB-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zDeWlEPTB;MkSuNFE6PCEQvF2= MWXTRW5ITVJ?
TK10 NUP2UXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTxW4F2UUN3ME2yOE42ODF|IN88US=> NX2zfWFKW0GQR1XS
LB373-MEL-D MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvLWow4UUN3ME2yOE43ODZ2IN88US=> Mn3IV2FPT0WU
KALS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ2LkezNlch|ryP MXLTRW5ITVJ?
HUTU-80 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf3[G5KSzVyPUK1MlgxOzJizszN MYDTRW5ITVJ?
HuP-T3 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzdXpRUUN3ME2yOk4yPjd2IN88US=> MlqzV2FPT0WU
OE19 NUjCfoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThRno2UUN3ME2yOk4zOTV|IN88US=> MkLLV2FPT0WU
J82 NFHTXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2yTWM2OD1{Nj6yOFcyKM7:TR?= NEDLNppUSU6JRWK=
DU-4475 NYS0SIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnoRXRKSzVyPUK2MlM5OTlizszN MV7TRW5ITVJ?
DMS-53 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPkd413UUN3ME2yOk42OTN6IN88US=> MUnTRW5ITVJ?
COLO-741 NVju[VQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOzTWM2OD1{Nj64N|Q1KM7:TR?= NYHJ[oZuW0GQR1XS
SW48 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfrOGlKSzVyPUK2Mlg5OiEQvF2= NFrEbJBUSU6JRWK=
IGR-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH2cFlKSzVyPUK2Mlk{OzRizszN MlvyV2FPT0WU
639-V M4XvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GxWWlEPTB;MkeuNFI1PSEQvF2= MkToV2FPT0WU
LK-2 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofhTWM2OD1{Nz60NVQyKM7:TR?= NWPQU2JuW0GQR1XS
NCI-H2347 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXmfFlKSzVyPUK3Mlk3QTlizszN M3qwdXNCVkeHUh?=
NCI-H2228 NVXZ[op4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XLfGlEPTB;MkiuNFkxPSEQvF2= MlzGV2FPT0WU
LS-123 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZSmlEPTB;MkiuNVI3OiEQvF2= NXPBRpMxW0GQR1XS
U031 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ6LkK1NkDPxE1? MnL3V2FPT0WU
NCI-H1792 M1\Ffmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK1[mR2UUN3ME2yPE41PzJzIN88US=> NFXZWHJUSU6JRWK=
NCI-H2087 NUPuO|FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u0S2lEPTB;MkiuO|U2OiEQvF2= MmnmV2FPT0WU
NCI-H2342 NULaNmZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfnN3c2UUN3ME2yPU42OjB6IN88US=> NWrUdItNW0GQR1XS
SW626 NXLjfFV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PHUWlEPTB;MkmuO|U3KM7:TR?= NHu3R4JUSU6JRWK=
LB2518-MEL M1jjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXmfoY4UUN3ME2yPU45OTVizszN MXLTRW5ITVJ?
RXF393 NUTFNYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fEOGlEPTB;M{CuNFk2OiEQvF2= MUDTRW5ITVJ?
LC4-1 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTITWM2OD1|MD6zNFkzKM7:TR?= M2S2b3NCVkeHUh?=
NCI-H1694 NEK2eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXNTYF4UUN3ME2zNE43PjJ2IN88US=> MkXRV2FPT0WU
K5 NFK0RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDaT2dXUUN3ME2zNE46PzB{IN88US=> NHexbmtUSU6JRWK=
HDLM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W2OGlEPTB;M{CuPVczPSEQvF2= M1XwXHNCVkeHUh?=
BCPAP MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W1OWlEPTB;M{GuPFM4QSEQvF2= NH7XRWxUSU6JRWK=
BC-3 NH7FU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTN{LkG0NFMh|ryP NUnzNmFjW0GQR1XS
LB996-RCC NXPsTIh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzz[Y9KSzVyPUOyMlI{PThizszN NWjOWXhRW0GQR1XS
NCI-H2009 M4fWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5O3M2UUN3ME2zNk41QThzIN88US=> NVTYd3FFW0GQR1XS
HTC-C3 NXW3UmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzWTWM2OD1|Mz63OVE6KM7:TR?= NGPCUo5USU6JRWK=
LAMA-84 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPEPIRKSzVyPUO0MlQ1ODdizszN M2DDTXNCVkeHUh?=
CCRF-CEM MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHjV3AxUUN3ME2zOE42PzF3IN88US=> NH\VdHZUSU6JRWK=
AN3-CA NGe5O5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHK[IRoUUN3ME2zOU4xPTZ6IN88US=> Mm\RV2FPT0WU
NCI-H1734 NFHRblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN3LkK1OlEh|ryP NIf6VYNUSU6JRWK=
Ca-Ski NGPMTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPwVXBkUUN3ME2zOU41OTBzIN88US=> Mo\OV2FPT0WU
U-266 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3nUFR5UUN3ME2zOU43OTF2IN88US=> NF7ueXhUSU6JRWK=
SBC-5 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TpNWlEPTB;M{WuO|c5OSEQvF2= NX\sRWxpW0GQR1XS
GT3TKB MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTN5LkGxOUDPxE1? MlPQV2FPT0WU
MDA-MB-175-VII Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInXVGJKSzVyPUO3MlIzPDhizszN MX7TRW5ITVJ?
PFSK-1 NUfsco11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5UZM3UUN3ME2zO{4zPDN3IN88US=> M{fQ[3NCVkeHUh?=
IMR-5 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN5LkK0PFch|ryP M4L3T3NCVkeHUh?=
Daudi MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXEfmNzUUN3ME2zO{4{PTl5IN88US=> MmW4V2FPT0WU
A498 NV7WS|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN5LkeyNVgh|ryP MkjqV2FPT0WU
SCC-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPMblUyUUN3ME2zO{44QDR|IN88US=> NWnKXGFFW0GQR1XS
COLO-680N M{LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN6LkK4PFUh|ryP MoLwV2FPT0WU
SK-MES-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjiTWM2OD1|OD6zNlE2KM7:TR?= MkDpV2FPT0WU
SR NVLERolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\pTWM2OD1|OD61OFk2KM7:TR?= MX;TRW5ITVJ?
LNCaP-Clone-FGC NWXETZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLRTWM2OD1|OD61OlM4KM7:TR?= NWfKPWtbW0GQR1XS
SK-HEP-1 M2nST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD6coRnUUN3ME2zPE44QDJ{IN88US=> M2[4WnNCVkeHUh?=
BPH-1 NVT6VoNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPYU3pTUUN3ME2zPE45OzJ7IN88US=> NIPzfGxUSU6JRWK=
NCI-H1755 NFf2[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HlR2lEPTB;M{muOVgyPyEQvF2= MnPvV2FPT0WU
LXF-289 NVnSS49KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN7LkiwPFQh|ryP Mn3GV2FPT0WU
SW1088 M4TG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\yTWM2OD12MD6yNVA4KM7:TR?= NFPhZnRUSU6JRWK=
MOLT-4 NX\nVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LiXWlEPTB;NECuNlkxOSEQvF2= M1:xbnNCVkeHUh?=
AsPC-1 M2Xse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;WU4dKSzVyPUSwMlQ2QDNizszN MnrQV2FPT0WU
HOP-62 M{TuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRyLk[1Olgh|ryP M12xTHNCVkeHUh?=
A172 M3PaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD12MD64OVEyKM7:TR?= MnnyV2FPT0WU
SN12C NVKwNFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;oTWM2OD12MD65N|g2KM7:TR?= M1;VPHNCVkeHUh?=
MDA-MB-231 NI\XdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PEdmlEPTB;NECuPVg6QCEQvF2= NEX5R41USU6JRWK=
RPMI-2650 NXXuU3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmyZVlKSzVyPUSxMlE2QTNizszN M1jWeHNCVkeHUh?=
KYSE-140 NUi2e|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTRzLkixNlMh|ryP MU\TRW5ITVJ?
KINGS-1 NXHBNG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vqOGlEPTB;NEKuOFY6PyEQvF2= M3zhW3NCVkeHUh?=
HSC-3 M2fOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPyTWM2OD12Mj62OlYyKM7:TR?= MoLKV2FPT0WU
PC-14 M3;oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT3TWM2OD12Mz6xPFgzKM7:TR?= Mn[3V2FPT0WU
COR-L105 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR|Lk[1NFIh|ryP MUHTRW5ITVJ?
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfWPYhNUUN3ME20OE4zOzdzIN88US=> NYnvSZNYW0GQR1XS
NCI-H661 NIjMU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUNWZFUUN3ME20OE4zQTV6IN88US=> M2LTdXNCVkeHUh?=
IST-MEL1 NVjTbmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETLUmJKSzVyPUS0MlM2QTlizszN M3ftOnNCVkeHUh?=
HCC1806 M1HxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\lemJKSzVyPUS0MlU5PzNizszN MXfTRW5ITVJ?
COLO-800 M3HsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj6SlFKSzVyPUS0Mlg1PTNizszN NF72e4pUSU6JRWK=
IST-SL2 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWSmdKSzVyPUS1MlEzPDdizszN M1TMNnNCVkeHUh?=
8305C MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XKWGlEPTB;NEWuN|A6KM7:TR?= NHL1SGZUSU6JRWK=
UACC-62 M{jrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHntUHRKSzVyPUS2MlI5PzVizszN MmrCV2FPT0WU
COR-L23 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPWTWM2OD12Nz6xPVkh|ryP MYfTRW5ITVJ?
EFE-184 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDCVnRmUUN3ME20O{4{QDhizszN NYrHNpVEW0GQR1XS
DMS-114 NULlZmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXZe3dKSzVyPUS3MlQyPDlizszN MX3TRW5ITVJ?
KYSE-520 M2\JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTR6LkWzNVUh|ryP Mm\EV2FPT0WU
SNG-M MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTR7LkSzOEDPxE1? NHXv[VdUSU6JRWK=
A2058 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi2TWM2OD12OT60PFg2KM7:TR?= NHewbotUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1(O)CC(C1)C2=NC(=C3[N]2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib|Linsitinib ic50|Linsitinib price|Linsitinib cost|Linsitinib solubility dmso|Linsitinib purchase|Linsitinib manufacturer|Linsitinib research buy|Linsitinib order|Linsitinib mouse|Linsitinib chemical structure|Linsitinib mw|Linsitinib molecular weight|Linsitinib datasheet|Linsitinib supplier|Linsitinib in vitro|Linsitinib cell line|Linsitinib concentration|Linsitinib nmr|Linsitinib in vivo|Linsitinib clinical trial|Linsitinib inhibitor|Linsitinib Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID